Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.19.1
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenue
Expenses:    
Research and development 3,340 3,140
General and administrative 2,260 3,702
Operating Expenses 5,600 6,842
Other income (expense):    
Interest income 92 44
Foreign exchange gains/( losses) 2 (16)
Total other income 94 28
Net loss (5,506) (6,814)
Other comprehensive loss:    
Unrealized gain/(losses) on securities available-for-sale 9 (2)
Total comprehensive loss $ (5,497) $ (6,816)
Basic and diluted loss per common share (in dollars per share) $ (0.14) $ (0.23)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (in shares) 39,846 29,042